

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **GOLDSTREAM INVESTMENT LIMITED**

**金涌投資有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1328)**

**(1) RESIGNATION OF EXECUTIVE DIRECTOR,  
CHIEF EXECUTIVE OFFICER,  
AUTHORISED REPRESENTATIVE AND PROCESS AGENT  
(2) APPOINTMENT OF CHIEF EXECUTIVE OFFICER  
AND  
(3) APPOINTMENT OF AUTHORISED REPRESENTATIVE  
AND PROCESS AGENT**

**RESIGNATION OF EXECUTIVE DIRECTOR, CHIEF EXECUTIVE OFFICER,  
AUTHORISED REPRESENTATIVE AND PROCESS AGENT**

The board (the “**Board**”) of directors (the “**Director(s)**”) of Goldstream Investment Limited (the “**Company**”) hereby announces that Dr. Lin Tun (“**Dr. Lin**”) has tendered his resignation as (i) an executive Director, (ii) the Chief Executive Officer of the Company (the “**Chief Executive Officer**”), (iii) one of the authorised representatives as required under Rule 3.05 (the “**Authorised Representative**”) of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”); and (iv) an authorised representative for accepting service of process and notices on behalf of the Company as required under Part 16 of the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) and Rule 19.05(2) of the Listing Rules (the “**Process Agent**”) with effect from 31 May 2022 due to his personal reasons to focus on his personal affairs.

Dr. Lin has confirmed that he has no disagreement with the Board and there is no matter in relation to his resignation that needs to be brought to the attention of the shareholders of the Company.

The Board would like to express its gratitude to Dr. Lin for his valuable efforts and contributions to the Company during his tenure of office.

## **APPOINTMENT OF CHIEF EXECUTIVE OFFICER**

Subsequent to the resignation of Dr. Lin, Mr. Zhao John Huan (“**Mr. Zhao**”), an executive Director and the Chairman of the Board, has been appointed as the Chief Executive Officer with effect from 31 May 2022.

Mr. Zhao, aged 59, was appointed an executive Director in December 2018. He is the chairman of Hony Capital Limited (“**Hony Capital**”) which is an alternative investment management group focusing on opportunities in China. Mr. Zhao has extensive experience in senior management positions at several public companies, including as a non-executive director of Legend Holdings Limited (stock code: 3396.HK), a non-executive director of China Glass Holdings Limited (stock code: 3300.HK) a non-executive director of Lenovo Group Limited (stock code: 992.HK), a non-executive director of Zoomlion Heavy Industry Science and Technology Co., Ltd. (stock code: 1157.HK, 000157.SZ), an executive director and the chairman of the board of Best Food Holding Company Limited (stock code: 1488.HK), a non-executive director of ENN Natural Gas Co., Ltd. (SSE: 600803), a non-executive director of Simcere Pharmaceutical Group Limited (stock code: 2096.HK) and was a non-executive director of Eros STX Global Corporation (NYSE: ESGC) until April 2022 and a non-executive director of Shanghai Jin Jiang International Hotels Co., Ltd. (stock code: 600754.SH) until May 2022.

Mr. Zhao graduated with a bachelor’s degree in Physics from Nanjing University. He also obtained dual Master’s degrees in Electronic Engineering and Physics from Northern Illinois University, and a master of management degree from the Kellogg School of Management at Northwestern University.

Mr. Zhao has entered into a service agreement with the Company for an initial term of three years, commencing on 28 December 2018, and will continue thereafter for successive three-year terms. Mr. Zhao is subject to retirement from office and re-election in accordance with the Listing Rules and the articles of association of the Company. Mr. Zhao will not receive any remuneration for serving as a Director, the Chairman and the Chief Executive Officer.

As at the date of this announcement, Mr. Zhao has deemed interest in 7,802,539,321 shares of the Company through his controlled corporations.

Save as disclosed, Mr. Zhao (i) does not have any interest in the shares or underlying shares of the Company (within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong)); (ii) does not hold any other positions in the Company or its subsidiaries; (iii) does not have any relationship with any other Directors, senior management, substantial shareholders or controlling shareholders of the Company; and (iv) did not hold any directorship in other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years.

Code provision C.2.1 of the Corporate Governance Code contained in Appendix 14 to the Listing Rules stipulates that the role of the chairman of the board and the chief executive officer should be separate and should not be performed by the same individual. After Mr. Zhao has been appointed as the Chief Executive Officer, there is no separation between the roles of the Chairman and the Chief Executive Officer. Although the responsibilities of the Chairman and the Chief Executive Officer are vested in one person, all major decisions are made in consultation with the members of the Board and the senior management of the Company. The Board also considers that the current structure allows efficient implementation of the Company's strategies.

Save as disclosed above, there are no other matters relating to the appointment of Mr. Zhao that need to be brought to the attention of the shareholders of the Company and there is no information which is required to be disclosed pursuant to any of the requirements of Rule 13.51(2)(h) to (v) of the Listing Rules.

## **APPOINTMENT OF AUTHORISED REPRESENTATIVE AND PROCESS AGENT**

Following the resignation of Dr. Lin, the Board is pleased to announce that in replacement of Dr. Lin, Mr. Tam Terry Sze Ying, the non-executive Director of the Company, has been appointed as the Authorised Representative and the Process Agent with effect from 31 May 2022.

By order of the Board  
**Goldstream Investment Limited**  
**Mr. Zhao John Huan**  
*Chairman of the Board*

Hong Kong, 31 May 2022

*As at the date of this announcement, the Board comprises one executive Director, namely Mr. Zhao John Huan (Chairman and Chief Executive Officer); one non-executive Director, namely Mr. Tam Terry Sze Ying; and three independent non-executive directors, namely Mr. Jin Qingjun, Mr. Lee Kin Ping Christophe, and Mr. Shu Wa Tung Laurence.*